2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 – small molecules by LCMS)

Author:

Welink Jan1,Fluhler Eric2,Hughes Nicola3,Arnold Mark4,Garofolo Fabio5,Bustard Mark6,Coppola Laura7,Dhodda Raj8,Evans Christopher9,Gleason Carol10,Haidar Sam11,Hayes Roger12,Heinig Katja13,Katori Noriko14,Blaye Olivier Le15,Li Wenkui16,Liu Guowen4,Lima Santos Gustavo Mendes17,Meng Min18,Nicholson Bob19,Savoie Natasha20,Skelly Michael11,Sojo Luis21,Tampal Nilufer6,de Merbel Nico van22,Verhaeghe Tom23,Vinter Stephen24,Wickremsinhe Enaksha25,Whale Emma24,Wilson Amanda26,Witte Bärbel27,Woolf Eric28

Affiliation:

1. Dutch MEB, Utrecht, The Netherlands

2. Pfizer, Pearl River, NY, USA

3. Bioanalytical Laboratory Services a Division of LifeLabs LP, Toronto, ON, Canada

4. Bristol-Myers Squibb, Princeton, NJ, USA

5. Angelini Pharma, Piazzale della Stazione, snc, 0040 S. Palomba Pomezia (RM), Italy

6. Health Canada, Ottawa, ON, Canada

7. Apotex, Toronto, ON, Canada

8. AbbVie Inc., North Chicago, IL, USA

9. GlaxoSmithKline, King of Prussia, PA, USA

10. Bristol-Myers Squibb, Tully, NY, USA

11. US FDA, Silver Spring, MD, USA

12. MPI Research, Mattawan, MI, USA

13. F. Hoffmann-La Roche Ltd., Basel, Switzerland

14. Japan MHLW-NIHS, Tokyo, Japan

15. France ANSM, Saint-Denis, France

16. Novartis, East Hanover, NJ, USA

17. Brazil Anvisa, Brasilia, Brazil

18. Covance, Salt Lake City, UT, USA

19. PPD, Richmond, VA, USA

20. CFABS, Montreal, QC, Canada

21. Xenon Pharmaceuticals Inc., Burnaby, BC, Canada

22. PRA Health Sciences, Assen, The Netherlands

23. Janssen Research & Development, Beerse, Belgium

24. UK MHRA, London, UK

25. Eli Lilly & Company, Indianapolis, IN, USA

26. AstraZeneca, Cambridge, UK

27. Germany BfArM, Bonn, Germany

28. Merck Research Labs, West Point, PA, USA

Abstract

The 2015 9th Workshop on Recent Issues in Bioanalysis (9th WRIB) took place in Miami, Florida with participation of over 600 professionals from pharmaceutical and biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. It is once again a 5-day week long event – a full immersion bioanalytical week – specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches including the focus on biomarkers and immunogenicity. This 2015 White Paper encompasses recommendations that emerged from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to advance scientific excellence, improve quality and deliver better regulatory compliance. Due to its length, the 2015 edition of this comprehensive White Paper has been divided into three parts. Part 1 covers the recommendations for small molecule bioanalysis using LCMS. Part 2 (hybrid LBA/LCMS and regulatory agencies’ inputs) and Part 3 (large molecule bioanalysis using LBA, biomarkers and immunogenicity) will also be published in volume 7 of Bioanalysis, issues 23 and 24, respectively.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

2. 2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies);Bioanalysis;2024-04-17

3. 2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization);Bioanalysis;2024-02-22

4. 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization;Bioanalysis;2023-08

5. 2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3